Sorin Group scored a big win in Japan--regulatory approval for its Mitroflow aortic pericardial heart valve.
The Italian cardiac device giant termed the Japanese Pharmaceuticals and Medical Devices Agency approval as "a key achievement" for the company. And it is, considering Japan is among the world's largest markets for medical devices.
The valve replacement is also designed to work well with patients who have a small or narrow aortic root, something that can often happen with Japanese patients, the company notes.
Sorin has focused on diversifying its cardiac offerings in recent months. The company invested $5.4 million in French percutaneous mitral valve replacement startup HighLife SAS, and also committed an $8 million investment to Cardiosolutions, a U.S. developer of less invasive devices and surgical tools for a number of heart conditions. Meanwhile, the company has focused on rebounding from an earthquake at the end of May that hammered production and negatively impacted both revenue and net profit.
- read the release
Sorin commits $5.4M to percutaneous mitral valve replacement startup
Sorin devotes $8M to Cardiosolutions
Given Imaging soars after filing for Japanese approval